E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Inclusion Criteria: * Age \>= 18 years * Histologically or cytologically confirmed stage IV metastatic BRAF V600-mutated melanoma * Documented metastasis of the primary tumor to the CNS * BRAF-mutation melanoma tumor status will be established prior to entry based on previous BRAF-gene analysis reports from a Clinical Laboratory Improvement Act (CLIA) qualified laboratory. If a report is not available, the mutation analysis will be performed at screening on archival tissue * At least one brain metastasis, as assessed by magnetic resonance imaging (MRI) or computed tomography (CT) with contrast =\< 3 weeks prior to registration and does not require immediate local intervention (surgery or radiosurgery) * Asymptomatic or symptomatic CNS metastasis * Systemic, measurable metastatic melanoma disease is allowed; leptomeningeal disease is allowed. * Prior stereotactic radiosurgery and/or excision of brain metastases is allowed \> 3 weeks before initiation of study treatment * Prior immunotherapy for adjuvant or metastatic disease is allowed provided there is documented progression of disease following treatment * Prior melanoma adjuvant BRAF/MEK inhibitor treatment is allowed if \>= 12 months has elapsed between the end of therapy and initiation of study treatment * Able to swallow and retain oral medication with no clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels * Stable dose of corticosteroids for CNS metastasis is allowed if \>= 7 days * Seizures due to CNS metastases must be controlled with stable anti-epileptic treatment for \>= 14 days * Bisphosphonates and/or denosumab are allowed * Life expectancy \>= 3 months * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * Hemoglobin (Hb) \>= 9 g/dL without ongoing transfusional support (obtained =\< 15 days prior to registration) * Absolute neutrophil count (ANC) \>= 1.0 x 10\^9 cells/L without ongoing transfusional support (obtained =\< 15 days prior to registration) * Platelets \>= 75 x 10\^9 cells/L without ongoing transfusional support (obtained =\< 15 days prior to registration) * Creatinine =\< 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance \>= 50 mL/minute per the Cockcroft-Gault formula (obtained =\< 15 days prior to registration) * Total bilirubin =\< 2 times the upper limit of normal (ULN) unless due to Gilbert's disease (obtained =\< 15 days prior to registration) * Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =\< 2.5 times ULN, or \< 5 times ULN for subjects with liver metastases (obtained =\< 15 days prior to registration) * Negative serum pregnancy test done =\< 14 days prior to registration, for persons of childbearing potential only, defined as a female who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months) * Willing to use contraception * Sexually active persons of childbearing potential (PCBP) and persons able to father a child must agree to use adequate methods to avoid pregnancy throughout the study and for 28 days after the completion of study treatment * Provide written informed consent * Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study) * Ability to complete Patient Medication Diaries by themselves or with assistance * Willingness to have institution procure previous BRAF-gene analysis report(s) from a CLIA qualified laboratory, or if a report is not available, willingness to have institution procure archived tumor sample to establish BRAF-mutational melanoma tumor status prior to study * Ability to swallow Exclusion Criteria: * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Urgent need of treatment to prevent acute neurologic deterioration, including urgent neurosurgery or radiotherapy * Symptoms of uncontrolled intracranial pressure * Symptomatic or untreated spinal cord compression * Serious cardiac condition =\< 6 months prior to registration, such as uncontrolled arrhythmia, myocardial infarction, unstable angina, or heart disease defined by the New York Heart Association (NYHA) class III or class IV * Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment * Uncontrolled intercurrent non-cardiac illness including, but not limited to: * Ongoing or active infection requiring IV antibiotic usage within the last week prior to study treatment * Any other conditions that would limit compliance with study requirements or confound the interpretation of study results * Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial * Any of the following, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects: * Pregnant persons * Nursing persons * Persons of childbearing potential who are unwilling to employ adequate contraception